Maze Therapeutics Director Receives 18,000-Share Option Grant

Rhea-AI Filing Summary

Kathiresan Sekar, a director of Maze Therapeutics, Inc. (MAZE), reported the acquisition on 09/22/2025 of a stock option to buy 18,000 shares of common stock with an exercise price of $23.67. The option award vests in nine equal monthly tranches (1/9 each) beginning October 1, 2025, subject to continued service. The option shows an expiration or related date of 09/21/2035 and is reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact, Courtney Phillips, on 09/24/2025.

Positive

• Equity alignment: The option grant ties the director's compensation to company performance via equity ownership
• Retention incentives: Monthly vesting beginning Oct 1, 2025, supports director retention over the near term

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director stock option grant for 18,000 shares at $23.67, vesting monthly over nine months starting Oct 1, 2025.

This filing documents a standard equity-based compensation grant to a company director. The award is structured as a stock option for 18,000 shares with an exercise price of $23.67 and direct ownership reported following the transaction. Vesting occurs in nine equal monthly tranches beginning October 1, 2025, subject to continued service, which implies retention-focused incentives rather than immediate dilution or cash impact. The report appears procedural and typical for director compensation disclosures.

Corporate Governance Expert

TL;DR: Typical governance disclosure showing a director equity grant with service-based vesting; no unusual terms disclosed.

The Form 4 indicates the issuer granted stock options to a director and that the reporting was completed via attorney-in-fact. The vesting schedule is service-based (monthly tranches) and the instrument is a standard option with a stated exercise price and expiration-related date. There are no disclosed accelerations, transfers, or indirect ownership arrangements. From a governance perspective, this is a routine compensation disclosure without apparent governance red flags in the text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kathiresan Sekar

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.67	09/22/2025		A		18,000		(1)	09/21/2035	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did MAZE director Kathiresan Sekar file on Form 4?

The filing reports acquisition of a stock option to buy 18,000 shares of Maze Therapeutics common stock on 09/22/2025.

What is the exercise price and term for the options reported by MAZE director Sekar?

The reported exercise price is $23.67. The filing lists a related date of 09/21/2035 associated with the option.

How does the reported option vest according to the Form 4?

The option vests in 1/9 of the total award monthly, with the first tranche vesting on October 1, 2025, subject to continued service.

Is the reported ownership direct or indirect for Kathiresan Sekar?

The filing reports the ownership form as direct (D) for the 18,000 optioned shares.

Who signed the Form 4 filing for Sekar and when?

The Form 4 is signed by Courtney Phillips as attorney-in-fact on 09/24/2025.